Orthocell (ASX:OCC) raised AU$17 million via the placing of 28,333,333 shares at AU$0.60 apiece to launch collagen nerve wrap Remplir in the US and to drive further growth.
The issue price represented a 12% discount to the 10-day volume weighted average price, according to a Friday filing with the Australian bourse.
Shares under the placement will be allotted on Oct. 31, the filing said.
Orthocell said it remains on schedule to release top-line results from its Remplir US market authorization study and submit its US market authorization application in the fourth quarter, the filing added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。